AXSOME THERAPEUTICS, INC. (AXSM)
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
Can-Fite Secures Japanese Patent Allowance for Namodenosons Anti-Obesity Technology
Ermenegildo Zegna Group Reports Voting Results of the Annual General Meeting Held on June 26, 2026
Aurora Mobile’s JPush Empowers Yuanda Information’s Caiyuan Gungun App with Millisecond-Level, Precise User Engagement
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
Kyivstar and Ukraine’s Securities Regulator Sign Memorandum to Advance Capital Markets Development and Expand Investment Access
Tilray Medical Expands Medical Cannabis Access for Veterans Through Lyphe Clinic at Aldershot’s Armed Forces Weekend
Balchem Corporation to Participate in the CJS Securities 26th Annual New Ideas Summer Conference on July 9, 2026
Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update
Baker Hughes Announces Dates for Second-Quarter Earnings Release and Webcast